fig4
From: Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
Figure 4. PFS of ICIs in EGFR-mutant NSCLC: (A) PFS in tumors with WT NSCLC or EGFR-mutant NSCLC; (B) PFS by PD-L1 expression levels; (C) PFS by treatment modality; (D) PFS by mutation type; and (E) PFS by T790M mutation status. ICIs: Immune checkpoint blockades; PFS: progression-free survival; WT: wild type; EGFR: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer.
